MDA5功能获得性突变中的JAK 1/2阻断 - Suppr

JAK 1/2 Blockade in MDA5 Gain-of-Function.

作者信息

McLellan Kirsty E, Martin Neil, Davidson Joyce E, Cordeiro Nuno, Oates Bridget D, Neven Bénédicte, Rice Gillian I, Crow Yanick J

机构信息

Paediatric Rheumatology, Royal Hospital for Children, 1345 Govan Road, Glasgow, G514TF, UK.

Rainbow House Child Development Centre, Ayrshire General Hospital, Kilwinning Road, Irvine, KA128SS, UK.

出版信息

J Clin Immunol. 2018 Nov;38(8):844-846. doi: 10.1007/s10875-018-0563-2. Epub 2018 Nov 15.

DOI:10.1007/s10875-018-0563-2

PMID:30443754

Abstract

摘要

相似文献

JAK 1/2 Blockade in MDA5 Gain-of-Function.MDA5功能获得性突变中的JAK 1/2阻断

J Clin Immunol. 2018 Nov;38(8):844-846. doi: 10.1007/s10875-018-0563-2. Epub 2018 Nov 15.

An open-label trial of JAK 1/2 blockade in progressive -associated neuroinflammation.一项关于JAK 1/2阻断剂在进行性相关神经炎症中的开放标签试验。

Neurology. 2018 Feb 6;90(6):289-291. doi: 10.1212/WNL.0000000000004921. Epub 2018 Jan 10.

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.Janus激酶1/2抑制剂芦可替尼治疗3例与TMEM173激活突变相关的血管病变患儿的疗效

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.

Association of interferon-induced helicase C domain (IFIH1) gene polymorphisms with systemic lupus erythematosus and a relevant updated meta-analysis.干扰素诱导解旋酶C结构域（IFIH1）基因多态性与系统性红斑狼疮的关联及一项相关的更新荟萃分析。

Genet Mol Res. 2016 Oct 24;15(4):gmr-15-gmr15048008. doi: 10.4238/gmr15048008.

Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report.鲁索利替尼治疗Singleton-Merten 综合征的精准治疗：一例报告。

Pediatr Rheumatol Online J. 2022 Apr 11;20(1):24. doi: 10.1186/s12969-022-00686-7.

JAK inhibition in myelofibrosis.骨髓纤维化中的JAK抑制作用。

N Engl J Med. 2010 Dec 16;363(25):2464; author reply 2464-5; discussion 2465. doi: 10.1056/NEJMc1011635.

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.JAK1/2抑制剂芦可替尼治疗1例冻疮样狼疮

J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

[Systemic lupus erythematosus].[系统性红斑狼疮]

Internist (Berl). 2003 Dec;44(12):1557-71; quiz 1572-3. doi: 10.1007/s00108-003-1088-0.

Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis.JAK-STAT 通路（IFIH1、TYK2、IL-10）相关基因与系统性红斑狼疮关联的综合评估：一项荟萃分析。

Arch Dermatol Res. 2018 Nov;310(9):711-728. doi: 10.1007/s00403-018-1858-0. Epub 2018 Aug 31.

Anti-MDA5 antibody-positive juvenile dermatomyositis overlap with neuropsychiatric systemic lupus erythematosus: a case report.抗MDA5抗体阳性的青少年皮肌炎合并神经精神性系统性红斑狼疮：一例报告

Clin Exp Rheumatol. 2021 Jan-Feb;39 Suppl 128(1):27-28. Epub 2020 Nov 27.

引用本文的文献

Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells.二甲双胍可减轻RNASEH2突变的Aicardi-Goutières综合征细胞中的氧化损伤。

Genes (Basel). 2025 Jul 30;16(8):922. doi: 10.3390/genes16080922.

Interferon-α receptor antisense oligonucleotides reduce neuroinflammation and neuropathology in a mouse model of cerebral interferonopathy.干扰素-α 受体反义寡核苷酸可减少脑干扰素病小鼠模型中的神经炎症和神经病理学改变。

J Clin Invest. 2024 Jan 9;134(4):e169562. doi: 10.1172/JCI169562.

JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.JAK抑制在Aicardi-Goutières综合征中的应用：一项单中心多学科真实世界研究

J Clin Immunol. 2023 Aug;43(6):1436-1447. doi: 10.1007/s10875-023-01500-z. Epub 2023 May 12.

Breaking down the cellular responses to type I interferon neurotoxicity in the brain.解析 I 型干扰素诱导的脑神经元毒性的细胞反应。

Front Immunol. 2023 Feb 3;14:1110593. doi: 10.3389/fimmu.2023.1110593. eCollection 2023.

Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.病例报告：芦可替尼治疗的Aicardi-Goutières综合征中，新冠病毒感染后出现的全身性脂膜炎

Front Pediatr. 2022 Apr 25;10:837568. doi: 10.3389/fped.2022.837568. eCollection 2022.

DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes.DNA 损伤导致 Aicardi-Goutières 综合征星形胶质细胞的神经毒性炎症。

J Exp Med. 2022 Apr 4;219(4). doi: 10.1084/jem.20211121. Epub 2022 Mar 9.

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.托法替布治疗24例儿童风湿性疾病的安全性和有效性：单中心经验

Front Pediatr. 2022 Feb 8;10:820586. doi: 10.3389/fped.2022.820586. eCollection 2022.

Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.JAK 抑制剂在治疗先天性免疫缺陷中的新地位。

Front Immunol. 2021 Sep 17;12:717388. doi: 10.3389/fimmu.2021.717388. eCollection 2021.

Case Report: Aicardi-Goutières Syndrome and Singleton-Merten Syndrome Caused by a Gain-of-Function Mutation in IFIH1.病例报告：由IFIH1功能获得性突变引起的艾卡迪-古铁雷斯综合征和辛格尔顿-默滕综合征

Front Genet. 2021 May 13;12:660953. doi: 10.3389/fgene.2021.660953. eCollection 2021.

Immune Dysfunction in Mendelian Disorders of POLA1 Deficiency.POLA1 缺陷性孟德尔遗传病中的免疫功能障碍。

J Clin Immunol. 2021 Feb;41(2):285-293. doi: 10.1007/s10875-020-00953-w. Epub 2021 Jan 3.

本文引用的文献

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.巴瑞替尼治疗自身炎症性干扰素病的 JAK1/2 抑制作用。

J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.

An open-label trial of JAK 1/2 blockade in progressive -associated neuroinflammation.一项关于JAK 1/2阻断剂在进行性相关神经炎症中的开放标签试验。

Neurology. 2018 Feb 6;90(6):289-291. doi: 10.1212/WNL.0000000000004921. Epub 2018 Jan 10.

Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.I型干扰素介导的单基因自身炎症：I型干扰素病，概念概述。

J Exp Med. 2016 Nov 14;213(12):2527-2538. doi: 10.1084/jem.20161596. Epub 2016 Nov 7.

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20.

Neuromyelitis optica in a child with Aicardi-Goutières syndrome.患有Aicardi-Goutières综合征的儿童的视神经脊髓炎。

Neurology. 2015 Jul 28;85(4):381-3. doi: 10.1212/WNL.0000000000001792. Epub 2015 Jul 1.

Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.干扰素相关生物标志物在 TREX1、RNASEH2A、RNASEH2B、RNASEH2C、SAMHD1 和 ADAR 基因突变相关的 Aicardi-Goutières 综合征中的评估：病例对照研究。

Lancet Neurol. 2013 Dec;12(12):1159-69. doi: 10.1016/S1474-4422(13)70258-8. Epub 2013 Oct 30.

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.在骨髓纤维化患者停止使用芦可替尼治疗期间的严重不良事件。

Mayo Clin Proc. 2011 Dec;86(12):1188-91. doi: 10.4065/mcp.2011.0518. Epub 2011 Oct 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

JAK 1/2 Blockade in MDA5 Gain-of-Function.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献